BMO Capital Lowers PT on Gilead (GILD) to $75 Following Earnings, Reiterates Focus on TROPiCS-02 Data Readout
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman lowered the price target on Gilead Sciences (NASDAQ: GILD) to $75.00 (from $85.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
